Kyntra Bio (KYNB) Change in Receivables (2014 - 2026)
Kyntra Bio (KYNB) posted Change in Receivables of $4.8 million for Q1 2026, up 5031.91% sequentially from $94000.0 in Q4 2025, and up 52.66% YoY from $3.2 million in Q1 2025.
Kyntra Bio (KYNB) Change in Receivables (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Change in Receivables for 13 years, with the latest figure at $4.8 million in Q1 2026.
- Quarterly Change in Receivables rose 52.66% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 128.45% YoY) and the FY2025 annual result came in at $2.5 million, down 62.25% from the prior year.
- Change in Receivables climbed to $4.8 million in Q1 2026 per KYNB's latest filing, from $94000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $26.5 million in Q1 2022 and troughed at -$30.6 million in Q2 2024.
- A 5-year average of $582705.9 and a median of $218000.0 in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables soared 2082.11% in 2022, then plunged 9144.04% in 2023.
- Over 5 years, Change in Receivables stood at $218000.0 in 2022, then slumped by 9144.04% to -$19.7 million in 2023, then jumped by 53.23% to -$9.2 million in 2024, then surged by 101.02% to $94000.0 in 2025, then soared by 5031.91% to $4.8 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $4.8 million, $94000.0, and -$552000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | -4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.69 Mn |
| Jun 30, 2026 | -4.69 Mn |
| Mar 31, 2026 | 4.82 Mn |
| Mar 31, 2026 | 4.82 Mn |
| Dec 31, 2025 | 94,000.00 |
| Dec 31, 2025 | 94,000.00 |
| Sep 30, 2025 | -552,000.00 |
| Sep 30, 2025 | -552,000.00 |
| Jun 30, 2025 | -159,000.00 |
| Jun 30, 2025 | -159,000.00 |
| Mar 31, 2025 | 3.16 Mn |
| Mar 31, 2025 | 3.16 Mn |
| Dec 31, 2024 | -9.22 Mn |
| Dec 31, 2024 | -9.22 Mn |
| Sep 30, 2024 | 21.92 Mn |
| Sep 30, 2024 | 21.92 Mn |
| Jun 30, 2024 | -30.65 Mn |
| Jun 30, 2024 | -30.65 Mn |
| Mar 31, 2024 | 24.69 Mn |
| Mar 31, 2024 | 24.69 Mn |